The US FDA has approved Novo Nordisk Victoza (liraglutide [rDNA] injection) label to include data showing superior blood sugar control and weight reduction when compared to Januvia (sitagliptin).

Label update also includes approval of combination therapy with basal insulin for the treatment of adults with type 2 diabetes.

The update is based on data from two randomized, open-label studies in adults with type 2 diabetes.

Novo Nordisk executive vice president and chief science officer Mads Thomsen said: "The data from these studies further demonstrate the strong clinical profile and the value of Victoza in the treatment of type 2 diabetes."